NZ601350A - Method of treating arthritis - Google Patents

Method of treating arthritis

Info

Publication number
NZ601350A
NZ601350A NZ601350A NZ60135008A NZ601350A NZ 601350 A NZ601350 A NZ 601350A NZ 601350 A NZ601350 A NZ 601350A NZ 60135008 A NZ60135008 A NZ 60135008A NZ 601350 A NZ601350 A NZ 601350A
Authority
NZ
New Zealand
Prior art keywords
treating arthritis
arthritis
medicament
abstract
variables
Prior art date
Application number
NZ601350A
Other languages
English (en)
Inventor
Philip Bardwell
Tariq Ghayur
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of NZ601350A publication Critical patent/NZ601350A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NZ601350A 2007-11-16 2008-11-14 Method of treating arthritis NZ601350A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98847907P 2007-11-16 2007-11-16
NZ585085A NZ585085A (en) 2007-11-16 2008-11-14 Method of treating arthritis using arylsulfonamide compounds

Publications (1)

Publication Number Publication Date
NZ601350A true NZ601350A (en) 2013-08-30

Family

ID=40291332

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ601350A NZ601350A (en) 2007-11-16 2008-11-14 Method of treating arthritis
NZ585085A NZ585085A (en) 2007-11-16 2008-11-14 Method of treating arthritis using arylsulfonamide compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ585085A NZ585085A (en) 2007-11-16 2008-11-14 Method of treating arthritis using arylsulfonamide compounds

Country Status (14)

Country Link
US (2) US20090176785A1 (enExample)
EP (1) EP2231159A1 (enExample)
JP (2) JP5450434B2 (enExample)
KR (1) KR101585848B1 (enExample)
CN (1) CN101969951B (enExample)
AU (1) AU2008322595B2 (enExample)
CA (1) CA2705294C (enExample)
DO (1) DOP2013000169A (enExample)
IL (2) IL205501A (enExample)
MX (1) MX2010005395A (enExample)
NZ (2) NZ601350A (enExample)
RU (2) RU2526201C2 (enExample)
WO (1) WO2009064938A1 (enExample)
ZA (1) ZA201003434B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
DK2550258T3 (en) 2010-03-25 2015-12-07 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
KR20180059560A (ko) 2010-10-29 2018-06-04 애브비 인코포레이티드 아폽토시스―유도제를 포함하는 고체 분산체
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
PH12013501006A1 (en) 2010-11-23 2022-03-30 Abbvie Ireland Unlimited Co Methods of treatment using selective bcl-2 inhibitors
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
ES2948287T3 (es) 2017-08-23 2023-09-07 Guangzhou Lupeng Pharmaceutical Company Ltd Derivados heterocíclicos condensados como inhibidores de Bcl-2 para el tratamiento de enfermedades neoplásicas
US12220419B2 (en) 2018-08-22 2025-02-11 Newave Pharmaceutical Inc. BCL-2 inhibitors
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2021066873A1 (en) 2019-10-03 2021-04-08 Newave Pharmaceutical Inc. Condensed heterocycles as bcl-2 inhibitors
PH12022551091A1 (en) 2019-11-05 2024-06-24 Abbvie Deutschland Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax
WO2021133817A1 (en) 2019-12-27 2021-07-01 Guangzhou Lupeng Pharmaceutical Company Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
AU2021228622A1 (en) 2020-02-24 2022-10-13 Guangzhou Lupeng Pharmaceutical Company Ltd. Hot melt extruded solid dispersions containing a BCL2 inhibitor
US20240166646A1 (en) 2020-12-22 2024-05-23 Newave Pharmaceutical Inc. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
WO1997013751A1 (en) * 1995-10-10 1997-04-17 Pfizer Inc. Indole carbamates as leukotriene antagonists
CN1425004A (zh) * 2000-03-21 2003-06-18 宝洁公司 含杂环侧链的n－取代的金属蛋白酶抑制剂
HU230302B1 (hu) * 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
GB0217431D0 (en) * 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
JP2007500703A (ja) * 2003-07-28 2007-01-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ベンズイミダゾール、ベンズチアゾールおよびベンゾキサゾール誘導体およびｌｔａ４ｈモジュレーターとしてのそれらの使用
EP1663979B1 (en) * 2003-09-03 2013-10-09 RaQualia Pharma Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
ES2257929B1 (es) * 2004-07-16 2007-05-01 Laboratorios Del Dr. Esteve, S.A. Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos.
TWI337608B (en) * 2005-05-12 2011-02-21 Abbott Lab Apoptosis promoters
US20060276464A1 (en) * 2005-05-13 2006-12-07 Wyeth Diarylsulfone sulfonamides and use thereof
US20080182845A1 (en) * 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection

Also Published As

Publication number Publication date
IL205501A0 (en) 2010-12-30
KR101585848B1 (ko) 2016-01-15
NZ585085A (en) 2012-08-31
MX2010005395A (es) 2010-06-02
CN101969951A (zh) 2011-02-09
CN101969951B (zh) 2012-10-31
JP2014065716A (ja) 2014-04-17
US20090176785A1 (en) 2009-07-09
WO2009064938A1 (en) 2009-05-22
KR20100099172A (ko) 2010-09-10
RU2472509C2 (ru) 2013-01-20
ZA201003434B (en) 2011-10-26
JP2011503199A (ja) 2011-01-27
WO2009064938A9 (en) 2009-08-06
RU2010123796A (ru) 2011-12-27
CA2705294C (en) 2016-05-17
JP5450434B2 (ja) 2014-03-26
CA2705294A1 (en) 2009-05-22
RU2526201C2 (ru) 2014-08-20
EP2231159A1 (en) 2010-09-29
US20160101109A1 (en) 2016-04-14
IL205501A (en) 2013-08-29
AU2008322595A1 (en) 2009-05-22
RU2012143212A (ru) 2014-04-20
JP5667684B2 (ja) 2015-02-12
IL227641A0 (en) 2013-09-30
AU2008322595B2 (en) 2014-01-30
DOP2013000169A (es) 2013-12-15

Similar Documents

Publication Publication Date Title
NZ601350A (en) Method of treating arthritis
NZ598972A (en) Spiro-indoline-piperidine derivatives as selective GPR-40 activators for treating diabetes
EA201201648A1 (ru) Стимуляторы sgc
MX2009007231A (es) Compuestos quimicos 637:piridopirimidindionas como inhibidores de la fosfodiesterasa 4.
MY156274A (en) COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION
MX2010002461A (es) (carboxilalquilenfenil)feniloxamidas, metodo para su produccion y uso de las mismas como medicamento.
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
MX2010002419A (es) (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento.
TN2009000132A1 (en) Substituted dihydropyrazolones for treating cardiovascular and haematological diseases
AU2011328009A8 (en) Compounds and methods for treating pain
MY158994A (en) Ampk modulators
EA201200102A1 (ru) Соединения, применимые в качестве лекарственных средств
TN2012000401A1 (en) Heterocyclic compound
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
HK1215579A1 (zh) 被取代的2，3-二氫苯並呋喃基化合物和其用途
TN2012000248A1 (en) Novel spiropiperidine compounds
PH12013500205A1 (en) Compounds and methods for skin repair
MY164641A (en) Use of sulphur-containing heteroaromatic acid analogues as bactericides
MX348024B (es) Compuestos de adamantilo.
WO2009074247A8 (de) Neue 2-aryl-thiazol-4-carbonsäureamid-derivate, deren herstellung und verwendung als arzneimittel
SG190947A1 (en) Compounds and methods for skin repair
WO2010072770A3 (en) Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering
WO2011009532A3 (de) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-derivate, verfahren zu deren herstellung und deren verwendung zur behandlung von krankheiten
MX2011012538A (es) Terapia de combinacion para el tratamiento del mieloma multiple.
WO2011000945A3 (en) Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: ABBVIE INC., US

Effective date: 20130801

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 14 NOV 2015 BY SPRUSON + FERGUSON

Effective date: 20140110

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 NOV 2016 BY THOMSON REUTERS

Effective date: 20151030

LAPS Patent lapsed